Topical and Injected Exosomes

Last reviewed 1 September 2026Reviewed quarterly
ExosomesRegulatoryMarketing claimsEvidence
Thin evidenceEvidence grade DPlausible mechanism, not enough good human data to call it.
The claim
Cell-derived signalling vesicles that regenerate skin, boost collagen and accelerate healing after procedures.
The verdict
Genuinely interesting biology, almost no controlled human facial data, and a regulatory position most clinics do not mention.
Worth it?
Not yet, at current prices. The mechanism may earn a better grade in a few years. Today you are paying for a hypothesis.
Jump to

The biology is real

Cells communicate by releasing membrane-bound vesicles carrying proteins, lipids and RNA. Those vesicles change the behavior of the cells that take them up. In laboratory models, preparations derived from mesenchymal stem cells promote fibroblast migration, collagen production and wound closure.

That is a legitimate and active area of research, and it is why this entry says thin evidence and not no.

What is missing

Almost everything that would let anyone grade it higher.

There are very few randomized, controlled human trials of exosome preparations applied to the aging face, and the ones that exist are small, short and usually funded by the product's manufacturer. Split-face designs with blinded assessors are what would settle this, and there are not many.

There is also no standardization. Products sold as exosomes vary enormously in their source tissue, isolation method, particle count, purity and storage. Two clinics can use the word for two preparations with little in common, which makes the literature difficult to pool and makes any individual result hard to generalize.

How it is being sold around that

Here is the part worth understanding, because it explains what you are being offered.

No exosome product is approved or licensed for any use, so no clinic can legally market an injection of one. What clinics do instead is sell it as a topical applied to skin immediately after microneedling — and microneedling has just opened thousands of channels through the epidermis. Putting a product on freshly microchannelled skin is a very different thing from putting it on intact skin, and everyone involved knows it. The topical framing is what keeps the transaction on the right side of the warning letters.

That is a regulatory workaround, and it does not tell you the product works. It tells you the seller has found a way to sell it.

The regulatory position

This is the part that gets left out of the consultation.

The FDA has stated publicly that there are no approved exosome products for these uses and has issued safety communications after adverse events following administration of unapproved preparations. Products are not being cleared as devices or approved as biologics for facial rejuvenation. A clinic offering them is offering something outside that framework.

That does not automatically make a product unsafe. It does mean that nobody is independently verifying what is in the vial.

Where it might land

The most plausible near-term use is post-procedure recovery, applied topically to skin that has just been resurfaced, where the barrier is open and the mechanism is closest to the biology. If good controlled data arrives for anything, it will probably be that.

The honest summary

Interesting science, marketed years ahead of its evidence, at prices that assume the evidence already exists. If a clinic tells you exosomes will regenerate your skin, a reasonable follow-up is to ask what controlled human data they are relying on and who manufactured the product.

Where I land

There is promising science here. There is no approved product, almost no human evidence, and an FDA that has issued safety notifications after serious infections. Tread carefully, and assume any clinic quoting you a benefit is overstating what has actually been shown.

If the goal is genuinely better skin quality, the tools with years of data behind them are the ones worth your money first.

What this is based on

  1. Public safety notification on exosome productsU.S. Food and Drug Administration · 2024
  2. Davies, Williams & Goldie, the therapeutic and commercial landscape of stem cell vesicles in regenerative dermatologyJournal of Controlled Release · 2023
  3. Rahman et al., complications in non-surgical aesthetic treatments — 457 studies and 231,475 documented complicationsAesthetic Plastic Surgery · 2025

Grades describe the quality of the human evidence, not my opinion of the treatment. Where the literature changes, the grade changes and the review date moves with it.

The full guide

All guides →

GLP-1 Weight Loss and the Face: What Empties, and What Puts It Back →

The medication is not damaging your face. Fast weight loss is, and it does it through discrete fat compartments that empty at different rates. That mechanism decides which treatments can realistically restore it.

Newsletter

The one email a week that isn't selling you something.

What changed in facial rejuvenation this week, one guide we updated, and why it matters. Written by Jay Keni, MD.

A weekly email, once we launch it. We don’t sell or share addresses, and we never add patients from practice records — privacy.